Journal of Clinical Endocrinology & Metabolism, Vol 80, 3311-3320, Copyright © 1995 by Endocrine Society

ARTICLES

Metabolic effects of sodium metavanadate in humans with insulin- dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies

AB Goldfine, DC Simonson, F Folli, ME Patti and CR Kahn
Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA.

To investigate the efficacy and mechanism of action of sodium metavanadate as an oral hypoglycemic agent, five insulin-dependent diabetes mellitus (IDDM) and five noninsulin-dependent diabetes mellitus (NIDDM) patients were studied before and after 2 weeks of oral sodium metavanadate (NaVO3; 125 mg/day). Glucose metabolism measured during a two-step euglycemic insulin clamp was not significantly increased by vanadate therapy in patients with IDDM, but was improved by 29% during the low dose (0.5 mU/kg.min) insulin infusion and 39% during the high dose (1.0 mU/kg.min) in patients with NIDDM. The changes in glucose metabolism were largely accounted for by an increase in nonoxidative glucose disposal, as measured by indirect calorimetry. Basal hepatic glucose production and suppression of hepatic glucose production by insulin were unchanged by vanadate therapy. There was a significant decrease in insulin requirements in the patients with IDDM (39.1 +/- 6.6 to 33.8 +/- 4.7 U/day; P < 0.05). Cholesterol levels significantly decreased in both IDDM (4.53 +/- 0.16 vs. 4.27 +/- 0.22 mmol/L; P = 0.06) and NIDDM (6.92 +/- 0.75 vs. 5.28 +/- 0.46 mmol/L; P < 0.05). After NaVO3 therapy, there was a 1.7- to 3.9-fold increase in basal mitogen-activated protein and S6 kinase activities in mononuclear cells from patients with IDDM and NIDDM that mimicked the effect of insulin stimulation in controls. The most common adverse effect of oral NaVO3 was mild gastrointestinal intolerance. These data suggest that vanadate or related agents may have a potential role as adjunctive therapy in patients with diabetes mellitus.

This article has been cited by other articles:

				S. Karmaker, T. K. Saha, and H. Sakurai Antidiabetic Activity of the Orally Effective Vanadyl-Poly ({gamma}-Glutamic Acid) Complex in Streptozotocin(STZ)-induced Type 1 Diabetic Mice J Biomater Appl, March 1, 2008; 22(5): 449 - 464. [Abstract] [PDF]

				I. Amoyal, E. Prus, and E. Fibach Vanadate Elevates Fetal Hemoglobin in Human Erythroid Precursors by Inhibiting Cell Maturation Experimental Biology and Medicine, May 1, 2007; 232(5): 654 - 661. [Abstract] [Full Text] [PDF]

				S. Garcia-Vicente, F. Yraola, L. Marti, E. Gonzalez-Munoz, M. J. Garcia-Barrado, C. Canto, A. Abella, S. Bour, R. Artuch, C. Sierra, et al. Oral Insulin-Mimetic Compounds That Act Independently of Insulin Diabetes, February 1, 2007; 56(2): 486 - 493. [Abstract] [Full Text] [PDF]

				S. Di Paolo, A. Teutonico, D. Leogrande, C. Capobianco, and P. F. Schena Chronic Inhibition of Mammalian Target of Rapamycin Signaling Downregulates Insulin Receptor Substrates 1 and 2 and AKT Activation: A Crossroad between Cancer and Diabetes? J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2236 - 2244. [Abstract] [Full Text] [PDF]

				G. Y. Yeh, D. M. Eisenberg, T. J. Kaptchuk, and R. S. Phillips Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes Diabetes Care, April 1, 2003; 26(4): 1277 - 1294. [Abstract] [Full Text] [PDF]

				M. W. Makinen and M. J. Brady Structural Origins of the Insulin-mimetic Activity of Bis(acetylacetonato)oxovanadium(IV) J. Biol. Chem., March 29, 2002; 277(14): 12215 - 12220. [Abstract] [Full Text] [PDF]

				M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications Diabetes Care, January 1, 2002; 25(1): 148 - 198. [Full Text] [PDF]

				M. Barbagallo, L. J. Dominguez, and L. M. Resnick Insulin-Mimetic Action of Vanadate: Role of Intracellular Magnesium Hypertension, September 1, 2001; 38(3): 701 - 704. [Abstract] [Full Text] [PDF]

				B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]

				G. Ceolotto, A. Gallo, M. Sartori, R. Valente, E. Baritono, A. Semplicini, and A. Avogaro Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1301 - 1305. [Abstract] [Full Text]

				K. Cusi, S. Cukier, R. A. DeFronzo, M. Torres, F. M. Puchulu, and J. C. P. Redondo Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1410 - 1417. [Abstract] [Full Text]

				T. M. Pederson, D. L. Kramer, and C. M. Rondinone Serine/Threonine Phosphorylation of IRS-1 Triggers Its Degradation: Possible Regulation by Tyrosine Phosphorylation Diabetes, January 1, 2001; 50(1): 24 - 31. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				G. R. Ehring, H. H. Kerschbaum, C. M. Fanger, C. Eder, H. Rauer, and M. D. Cahalan Vanadate Induces Calcium Signaling, Ca2+ Release-Activated Ca2+ Channel Activation, and Gene Expression in T Lymphocytes and RBL-2H3 Mast Cells Via Thiol Oxidation J. Immunol., January 15, 2000; 164(2): 679 - 687. [Abstract] [Full Text] [PDF]

				I. Goldwaser, J. Li, E. Gershonov, M. Armoni, E. Karnieli, M. Fridkin, and Y. Shechter L-Glutamic Acid gamma -Monohydroxamate. A POTENTIATOR OF VANADIUM-EVOKED GLUCOSE METABOLISM IN VITRO AND IN VIVO J. Biol. Chem., September 10, 1999; 274(37): 26617 - 26624. [Abstract] [Full Text] [PDF]

				N. A. Tritos and C. S. Mantzoros Syndromes of Severe Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3025 - 3030. [Full Text]

				P. A. Hulley, F. Gordon, and F. S. Hough Inhibition of Mitogen-Activated Protein Kinase Activity and Proliferation of an Early Osteoblast Cell Line (MBA 15.4) by Dexamethasone: Role of Protein Phosphatases Endocrinology, May 1, 1998; 139(5): 2423 - 2431. [Abstract] [Full Text] [PDF]

				I. A. Setyawati, K. H. Thompson, V. G. Yuen, Y. Sun, M. Battell, D. M. Lyster, C. Vo, T. J. Ruth, S. Zeisler, J. H. McNeill, et al. Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats J Appl Physiol, February 1, 1998; 84(2): 569 - 575. [Abstract] [Full Text] [PDF]

				J. J. Cunningham Micronutrients as Nutriceutical Interventions in Diabetes Mellitus J. Am. Coll. Nutr., February 1, 1998; 17(1): 7 - 10. [Abstract] [Full Text] [PDF]

				S. Verma, M. C. Cam, and J. H. McNeill Nutritional Factors that Can Favorably Influence the Glucose/Insulin System: Vanadium J. Am. Coll. Nutr., February 1, 1998; 17(1): 11 - 18. [Abstract] [Full Text] [PDF]

				G. Huyer, S. Liu, J. Kelly, J. Moffat, P. Payette, B. Kennedy, G. Tsaprailis, M. J. Gresser, and C. Ramachandran Mechanism of Inhibition of Protein-tyrosine Phosphatases by Vanadate and Pervanadate J. Biol. Chem., January 10, 1997; 272(2): 843 - 851. [Abstract] [Full Text] [PDF]

				B. Lu, D. Ennis, R. Lai, E. Bogdanovic, R. Nikolov, L. Salamon, C. Fantus, H. Le-Tien, and I. G. Fantus Enhanced Sensitivity of Insulin-resistant Adipocytes to Vanadate Is Associated with Oxidative Stress and Decreased Reduction of Vanadate (+5) to Vanadyl (+4) J. Biol. Chem., September 14, 2001; 276(38): 35589 - 35598. [Abstract] [Full Text] [PDF]